^
    12h
    Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections (clinicaltrials.gov)
    P1, N=104, Recruiting, University of Texas Southwestern Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    17h
    VA EradicateHP: Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (clinicaltrials.gov)
    P3, N=360, Not yet recruiting, VA Office of Research and Development | Trial completion date: Mar 2030 --> Jun 2030 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Mar 2029 --> Jun 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    2d
    Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention (clinicaltrials.gov)
    P1, N=0, Withdrawn, Northwell Health | N=24 --> 0 | Trial completion date: Sep 2025 --> Mar 2026 | Recruiting --> Withdrawn
    Enrollment change • Trial completion date • Trial withdrawal
    |
    minocycline
    6d
    Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) (clinicaltrials.gov)
    P2, N=61, Not yet recruiting, First People's Hospital of Hangzhou
    New P2 trial
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    7d
    CHARM: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris (clinicaltrials.gov)
    P=N/A, N=200, Active, not recruiting, Bausch Health Americas, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    7d
    Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1)
    |
    FLT3-ITD mutation • NPM1 mutation
    |
    Venclexta (venetoclax) • azacitidine • decitabine • Synribo (omacetaxine mepesuccinate)
    9d
    Prophylactic Antibiotics for Outpatient Urethral Bulking (clinicaltrials.gov)
    P4, N=150, Not yet recruiting, University of Miami
    New P4 trial
    10d
    TRI-AB trial (2024-520251-24-00)
    P4, N=618, Not yet recruiting, Odense University Hospital
    New P4 trial
    |
    piperacillin
    12d
    CT: Immediate Restoration of a New Implant With High Primary Stability (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Universidade do Porto
    New trial
    13d
    Randomized Controlled Trial of Duration of Antibiotic Prophylaxis in Head and Neck Surgery with Free Flap Reconstruction, HEDAX Trial (ACTRN12624000370505)
    P4, N=526, Recruiting, The Royal Melbourne Hospital, Melbourne Health | Not yet recruiting --> Recruiting
    Enrollment open
    13d
    Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) Domain Addendum - Immunoglobulin Stopping or Extension (Stop-Ig) (ACTRN12624000963527)
    P2/3, N=300, Recruiting, Monash University | Not yet recruiting --> Recruiting
    Enrollment open
    13d
    Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study). (PubMed, Ther Adv Infect Dis)
    Serum inflammatory cytokines, tumor necrosis factor (TNF)-α, granulocyte colony stimulating factor (G-CSF), interleukin (IL)-7, IL-15, and proliferation factors, transforming growth factor (TGF)-α, fibroblast growth factor (FGF)-2, and fms-like tyrosine kinase 3 ligand (Flt3-L), significantly decreased in group A. IL-8 and IFN-γ in nasal drip significantly decreased in both group A and B. Serious adverse events did not increase in CAM groups, though mild gastrointestinal and liver events occurred in group A. CAM is safe and potentially useful for improving partial COVID-related symptoms and exerting immunomodulation during COVID-19 pneumonia. Japan Registry of Clinical Trials (jRCT; registration number: jRCTs071210011; https://jrct.mhlw.go.jp/latest-detail/jRCTs071210011) on April 13, 2021.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • FGF (Fibroblast Growth Factor) • IL15 (Interleukin 15)